Compare Crispr Therapeutics AG (CRSP) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs JPMorgan Chase & Co — how do they compare? Crispr Therapeutics AG trades at $53.3 (market cap $4.88B), while JPMorgan Chase & Co trades at $333.03 (market cap $880.98B). The key difference: JPMorgan Chase & Co is far larger — about 180.5× Crispr Therapeutics AG's market cap, and JPMorgan Chase & Co pays a 1.99% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and JPMorgan Chase & Co for 127 Days on average.
| CRSP | JPM | |
|---|---|---|
Market Cap | $4.88B | $880.98B |
Volume | 2,861,747 | 7,721,661 |
Sector | Health | Financials |
52-Week High | $74.92 | $365.18 |
52-Week Low | $44.34 | $282.84 |
Typical Hold Time | 77 Days | 127 Days |
Enterprise Value | $3.30B | $1.82T |
Dividend Yield | — | 1.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% with bearish technical signals. The company shows negative profitability metrics including -$581.6M net income and -4,101.26% net margin for 2025, though revenue is expected to grow from $0 to $11M in 2026. Recent news highlights upcoming clinical data presentations and CASGEVY's commercial potential, with analyst consensus leaning bullish despite fundamental challenges.
The outlook remains speculative with significant cash burn but promising pipeline catalysts. Investment opportunity lies in gene-editing breakthroughs and CASGEVY adoption, while risks include sustained losses, clinical trial outcomes, and competitive pressure. Wall Street maintains a $67.83 price target, suggesting 30% upside if execution improves.
JPMorgan Chase & Co. (JPM) trades at $332.39, up 0.85% daily, with a bearish technical signal but strong fundamentals. Recent earnings show two beats out of three reported quarters, with Q3 2026 results pending. Revenue grew to $181.85B in 2025, though net income dipped to $57.05B. The stock is supported by a high ROE of 18.43% and a moderate P/E of 14.2, while analyst consensus is a 'Moderate Buy' with a $373.18 price target.
Outlook remains positive due to solid profitability and institutional support, but risks include geopolitical tensions, cybersecurity threats highlighted in recent news, and volatile cash flows. The stock offers value relative to peers, with upside potential if earnings momentum continues, though investors should monitor macroeconomic headwinds and upcoming Q3 earnings for direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
